Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Novartis Ag (NVS) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 163,339,392
  • Shares Outstanding, K 2,375,500
  • Annual Sales, $ 50,387 M
  • Annual Income, $ 17,783 M
  • 36-Month Beta 0.68
  • Price/Sales 3.26
  • Price/Book 2.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.28 +1.32%
on 11/23/16
74.51 -8.51%
on 11/09/16
-3.09 (-4.34%)
since 11/02/16
3-Month
67.28 +1.32%
on 11/23/16
82.24 -17.11%
on 09/22/16
-11.21 (-14.12%)
since 09/02/16
52-Week
67.28 +1.32%
on 11/23/16
88.49 -22.96%
on 12/30/15
-16.85 (-19.82%)
since 12/02/15

Most Recent Stories

More News
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

Findings from a Novartis clinical trial (ELIANA) evaluating efficacy and safety of CTL019, an investigational chimeric antigen receptor T cell (CAR T) therapy, in relapsed/refractory (r/r) pediatric and...

Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study

Novartis International AG / Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study . Processed and transmitted by Nasdaq Corporate...

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated...

David Epstein Joins as Special Advisor to Remedy Pharmaceuticals

Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing a life-saving hospital-based treatment to people affected by central nervous system (CNS)...

Eli Lilly's Taltz Gaining Ground in Psoriasis Market, Leaving Novartis' Cosentyx at Risk in 2017, according to Spherix Global Insights

At just over six months post launch, US dermatologists report a significant increase in familiarity with Eli Lilly's IL-17 inhibitor, coupled with a significant increase in the Taltz user base from prior...

Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda

Novartis International AG / Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely...

Company News for November 22, 2016

Companies In The News: TSN,FB,NVS,LOCK,SYMC

Novartis Buys Selexys on Favorable Phase II Data on SelG1

Novartis (NVS) acquired Selexys Pharmaceuticals following the receipt of results from the phase II SUSTAIN study for the treatment of patients with SCD.

Teva's Leukemia Drug Gets EU Approval in First-Line Setting

Teva Pharmaceutical Industries Ltd. (TEVA) announced that the European Commission has approved a label expansion of Trisenox.

Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar

Novartis AG's (NVS) generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 68.74
1st Resistance Point 68.46
Last Price 68.17
1st Support Level 67.73
2nd Support Level 67.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.